Moderna share price: what to expect from Q4 and full year results
In this article we look at the Moderna share price and estimates ahead of the Q4 and FY20 results.
When is the Moderna earnings date?
The Moderna earnings release date is scheduled for the 25 February 2021. The results will cover the groups fourth quarter (Q4) and full year earnings.
Moderna results preview: what does the Street expect?
While Moderna is expected to have seen revenue surge significantly for financial year 2020 (FY20), increases in clinical trial expenses, raw materials, manufacturing costs, personnel costs, as well as consulting and outside services costs are expected to keep earnings in negative territory for the year. Moderna is however expecting a positive net cash flow from operating activities for the full year, driven by customer deposits which were at approximately $1.2 billion as of September 2020.
Consensus estimates as sourced from Refinitiv Data arrive at the following, in terms of the groups upcoming results:
- FY20 revenue of $519 million expected from $60.21 million realised in FY19
- FY20 loss per share of $1.55 (same as in FY19)
How to trade the Moderna results
The two graphics below provide traders with both a retail short term view on the stock, as well as an institutional longer-term view on the Moderna share price, as to how market participants are positioned ahead of the full year earnings release.
A Thomson Reuters poll of 16 analysts maintain a long-term average rating of ‘hold’ for Moderna (as of the 22 February 2021), with two of these analysts recommending a strong buy, six buy, five hold and three sell ratings on the stock.
From a retail trader perspective (as of 22 February 2021), 93% of IG clients with open positions on Moderna expect the share price to rise over the near term, while 7% of IG clients with open positions expect the price to fall.
Moderna share price: technical analysis
The share price of Moderna has seen its uptrend accelerating sharply, particularly since November 2020, where promising test results saw the company emerge as one of the global leaders in terms of effective Covid-19 vaccines.
Since making a new short-term high, the share price of Moderna has pulled back to a low of $167.95 before once again forming a bullish price reversal (circled blue). Aggressive short term traders might consider the reversal a suggestion that the near term highs at $189.25 might be tested once again, using a close below the $167.95 reversal low as a stop loss consideration.
Longer term trend followers might however prefer to wait for a more sizeable correction back towards trend line support for long entry. Currently we have a confluence of horizontal gap and trend line support at around the $135.50 level.
- Moderna full year results are scheduled for release on the 25 February
- Group revenue for FY20 is expected to have increased by more than 100%
- A loss per share in line with FY19 is expected in FY20
- The average long-term broker rating for Moderna is ‘hold’
- IG clients with open positions on Moderna expect the price to rise in the near term
- A technical analysis view on the company shows an uptrend which has been accelerating, although trend followers might hope for a deeper pullback before looking for long entry
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get commission from just 0.08% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets